Merck & Co., Inc. (MRK)
- Previous Close
125.23 - Open
125.65 - Bid --
- Ask --
- Day's Range
124.90 - 126.11 - 52 Week Range
99.14 - 133.10 - Volume
6,365,781 - Avg. Volume
8,312,703 - Market Cap (intraday)
318.605B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
898.43 - EPS (TTM)
0.14 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 3.08 (2.46%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
137.02
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
Performance Overview: MRK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
Valuation Measures
Market Cap
317.21B
Enterprise Value
345.17B
Trailing P/E
894.50
Forward P/E
14.62
PEG Ratio (5yr expected)
0.10
Price/Sales (ttm)
5.31
Price/Book (mrq)
8.44
Enterprise Value/Revenue
5.74
Enterprise Value/EBITDA
49.97
Financial Highlights
Profitability and Income Statement
Profit Margin
0.61%
Return on Assets (ttm)
2.64%
Return on Equity (ttm)
0.90%
Revenue (ttm)
60.12B
Net Income Avi to Common (ttm)
365M
Diluted EPS (ttm)
0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
7.09B
Total Debt/Equity (mrq)
96.37%
Levered Free Cash Flow (ttm)
2.13B
Research Analysis: MRK
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: MRK
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.
Analyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingBearishPrice TargetWeekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingNeutralPrice Target